Serum Interleukin Profile in Patients with Graves Orbithopathy

1. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh). 1989;120(4):473-8.10.1530/acta.0.1200473Search in Google Scholar

2. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284-90.10.1016/S0002-9394(14)70276-4Search in Google Scholar

3. Mohaseb K, Linder M, Rootman J, et al. Development and validation of a patient symptom questionnaire to facilitate early diagnosis of thyroidassociated orbitopathy in graves' disease. Orbit. 2008;27(6):419-25.10.1080/0167683080241456619085296Search in Google Scholar

4. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 2001;55(3):283-303.10.1046/j.1365-2265.2001.01349.x11589671Search in Google Scholar

5. Eckstein AK, Lösch C, Glowacka D, et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93(8):1052-6.10.1136/bjo.2007.13726519221109Search in Google Scholar

6. 6.Cozma I, Cozma LS, Boyce RL - Variation in thyroid status in patients with Graves' orbitopathy. Acta Endo (Buc). 2009;5(2):191-198.10.4183/aeb.2009.191Search in Google Scholar

7. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639-44.10.1136/bjo.73.8.63910418352765444Search in Google Scholar

8. Terwee CB, Prummel MF, Gerding MN, et al. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2005;62(2):145-55.10.1111/j.1365-2265.2005.02186.x15670189Search in Google Scholar

9. Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol. 2003;148(5):491-5.10.1530/eje.0.148049112720530Search in Google Scholar

10. Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229-48.10.1016/j.beem.2011.11.00722632361Search in Google Scholar

11. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000;52(3):267-71.10.1046/j.1365-2265.2000.00959.x10718823Search in Google Scholar

12. Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M. Current insights into the pathogenesis of Graves' orbitopathy. Horm Metab Res. 2009;41(6):456-464.10.1055/s-0029-122093519530272Search in Google Scholar

13. Bellur SP, Bahn RS, Smith TJ. Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy. Endocrine Reviews. 2003;24(6):802-835.10.1210/er.2002-002014671007Search in Google Scholar

14. Pappa A, Lawson JMM, Calder V, et al. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol. 2000;84:517-522.10.1136/bjo.84.5.517172344910781517Search in Google Scholar

15. Han R, Smith TJ. Induction by IL-1β of Tissue Inhibitor of Metalloproteinase-1 in Human Orbital Fibroblasts: Modulation of Gene Promoter Activity by IL-4 and IFN-γ. J. Immun. 2005;174(5):3072-3079.Search in Google Scholar

16. Cawood TJ, Moriarty P, O’Farrelly P, O’Shea D. The effects of tumour necrosis factor-α and interleukin1 on an in vitro model of thyroidassociated ophthalmopathy; contrasting effects on adipogenesis. Eur J Endocrinol. 2006;155:395-403.10.1530/eje.1.0224216914593Search in Google Scholar

17. Krassas GE, Wiersinga W. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol. 2006;15:4777-78.Search in Google Scholar

18. Cawood TJ, Moriarty P, O’Farrelly P, O’Shea P. Smoking and Thyroid- Associated Ophthalmopathy: A Novel Explanation of the Biological Link. J Clin Endocrinol Metab. 2007;92:159-64.10.1210/jc.2006-182417047020Search in Google Scholar

19. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur J Endocrinol. 2008;15:8273-285.Search in Google Scholar

20. Wakelkamp IMMJ, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrin. 2003;58(3):280-287.Search in Google Scholar

21. Szucs-Farkas Zs, Toth J, Kollar J, et al. Volume Changes in Intra- and Extraorbital Compartments in Patients with Graves' Ophthalmopathy: Effect of Smoking. Thyroid. 2005;15(2):146-151.10.1089/thy.2005.15.14615753674Search in Google Scholar

22. ThorntonJ, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye. 2007;21:1135-1145.10.1038/sj.eye.670260316980921Search in Google Scholar

23. Wiersinga WM and Bartalena L. Epidemiology and Prevention of Graves' Ophthalmopathy. Thyroid. 2002;12(10):855-860.10.1089/10507250276101647612487767Search in Google Scholar

24. de Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrin Metab. 1999;77:51120-1124.Search in Google Scholar

25. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves' Disease, and Thyroid-Associated Ophthalmopathy. Thyroid. 2008;18(9):953-95. 10.1089/thy.2007.0405287949018713026Search in Google Scholar